title: Differentiation between early rheumatoid arthritis patients and healthy persons by conventional and dynamic contrast-enhanced magnetic resonance imaging.
abstract: OBJECTIVE
  To identify the magnetic resonance imaging (MRI) parameter that best differentiates healthy persons and patients with early rheumatoid arthritis (RA), and to investigated responsiveness to treatment of various MRI parameters.
  
  
  METHODS
  Conventional MRI and dynamic contrast-enhanced (DCE)-MRI of the hand were performed once for 26 healthy persons, and before and after 6 and 12 months of disease-modifying anti-rheumatic drug (DMARD) treatment for 14 early RA patients, using a 1.0-T MRI unit. One-slice DCE-MRI was analysed using Dynamika version 4.2. The number of enhancing voxels (Nvoxel), the initial rate of enhancement (IRE), the maximum enhancement (ME), ME×Nvoxel, and IRE×Nvoxel were calculated for wrist and 2nd-5th metacarpophalangeal (MCP) joints. Conventional MR images were evaluated using the RA MRI scoring system (RAMRIS) synovitis score.
  
  
  RESULTS
  Using DCE-MRI, enhancement was demonstrated in 61.5% of healthy persons and in 91.7% of RA patients at baseline, with a median Nvoxel of 3 and 362, respectively. At baseline, all parameters were higher for patients than for healthy persons (all p ≤ 0.003). Only one patient had a baseline RAMRIS synovitis score below the 95th percentile of the healthy persons. The corresponding number of patients was 3 for Nvoxel, ME×Nvoxel and IRE×Nvoxel, and 10 for IRE and ME. The RAMRIS synovitis score and IRE showed the highest responsiveness, with a standardized response mean (SRM) of -1.00 and -0.88, respectively.
  
  
  CONCLUSIONS
  The RAMRIS synovitis scoring of conventional MRI, and to a lesser extent the one-slice DCE-MRI parameters of synovial volume, differentiated early RA patients and healthy persons. The decrease in RAMRIS synovitis score, Nvoxel, and IRE showed sensitivity to change during treatment.
authors.affiliation: Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Glostrup University Hospital , Denmark.
authors.forename: M B
authors.initials: MB
authors.lastname: Axelsen
authors.forename: B J
authors.initials: BJ
authors.lastname: Ejbjerg
authors.forename: M L
authors.initials: ML
authors.lastname: Hetland
authors.forename: H
authors.initials: H
authors.lastname: Skjødt
authors.forename: O
authors.initials: O
authors.lastname: Majgaard
authors.forename: U B
authors.initials: UB
authors.lastname: Lauridsen
authors.forename: K
authors.initials: K
authors.lastname: Hørslev-Petersen
authors.forename: M
authors.initials: M
authors.lastname: Boesen
authors.forename: O
authors.initials: O
authors.lastname: Kubassova
authors.forename: H
authors.initials: H
authors.lastname: Bliddal
authors.forename: M
authors.initials: M
authors.lastname: Østergaard
mesh_terms: D000328:Adult; D018501:Antirheumatic Agents / Q000627:therapeutic use; D001172:Arthritis, Rheumatoid / Q000188:drug therapy / Q000473:pathology*; D016022:Case-Control Studies; D004305:Dose-Response Relationship, Drug; D005260:Female; D006801:Humans; D008279:Magnetic Resonance Imaging / Q000379:methods*; D008297:Male; D008662:Metacarpophalangeal Joint / Q000473:pathology*; D008875:Middle Aged; D012680:Sensitivity and Specificity; D013585:Synovitis / Q000188:drug therapy / Q000473:pathology; D013997:Time Factors; D014955:Wrist Joint / Q000473:pathology*
chemical_list: D018501:Antirheumatic Agents